Trastuzumab (Herceptin®; Genentech Inc, South San Francisco, CA), a humanized IgG1 mAb directed against HER2, was initially approved in 1998 in the United States for the treatment of HER2-overexpressing breast cancer [11]. This evidence concerns the gene ERBB2 and breast cancer.